A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : TU / testosterone undecanoate

[Related PubMed/MEDLINE]
Total Number of Papers: 153
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   TU  (>> Co-occurring Abbreviation)
Long Form:   testosterone undecanoate
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Accurate measurement of androgen after androgen esters: problems created by exvivo esterase effects and LC-MS/MS interference. DMA, DMAU
2019 CORRECTION OF ANDROGEN DEFICIENCY IN MEN WITH HYPOTHYROIDISM. ---
2019 Cryptozoospermia after treatment with clomiphene citrate following long-term use of intramuscular testosterone undecanoate depot injection (Nebido). CC, FSH, LH, SERM, TRT
2019 Pharmacokinetics and Acceptability of Subcutaneous Injection of Testosterone Undecanoate. DBS, DHT, PK, s.c
2019 Testosterone undecanoate supplementation together with human chorionic gonadotropin does not impair spermatogenesis in males with isolated hypogonadotropic hypogonadism: a retrospective study. hCG, IHH
2018 Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy. BMR, EG, HG, IM, SH, T2D
2018 Relationship between testosterone in serum, saliva and urine during treatment with intramuscular testosterone undecanoate in gender dysphoria and male hypogonadism. HG, ST, u-T
2018 Solidification of Nanostructured Lipid Carriers Loaded Testosterone Undecanoate: In Vivo and In Vitro Study. DSC, NLC, solid TU-NLC, TEM, TU-NLC
2017 Androgen Deprivation Accelerates the Prostatic Urethra Wound Healing After Thulium Laser Resection of the Prostate by Promoting Re-Epithelialization and Regulating the Macrophage Polarization. TmLRP
10  2017 Effectiveness and tolerability of parenteral testosterone undecanoate: a post-marketing surveillance study. ADR, PSA
11  2017 Novel double-layer Silastic testicular prosthesis with controlled release of testosterone in vitro, and its effects on castrated rats. LH, STPT, TUNEL
12  2017 Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. EF, FT, HG, SxD, TRT, TT
13  2016 Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism. LOH
14  2016 Emerging medication for the treatment of male hypogonadism. AI, CC, TRT
15  2016 Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability. SI, TST
16  2016 Suppression of spermatogenesis by testosterone undecanoate-loaded injectable in situ-forming implants in adult male rats. ISFI
17  2016 Testosterone replacement therapy improves the health-related quality of life of men diagnosed with late-onset hypogonadism. AMS, HRQoL, IPSS, LOH, TRT, TT
18  2016 Testosterone undecanoate improves lipid profile in patients with type 1 diabetes and hypogonadotrophic hypogonadism. T1D, Td
19  2016 Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. FT, HG, TT
20  2015 Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism. ED, MET, SHBG, TRT
21  2015 Complications of injectable testosterone undecanoate in routine clinical practice. POME
22  2015 Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. QOL
23  2015 Evaluation of 451 Danish boys with delayed puberty: diagnostic use of a new puberty nomogram and effects of oral testosterone therapy. CDGP, PAH
24  2015 Feasibility of poly (ϵ-caprolactone-co-DL-lactide) as a biodegradable material for in situ forming implants: evaluation of drug release and in vivo degradation. ISFI, MWs, NMP
25  2015 Importance of measuring testosterone in enzyme-inhibited plasma for oral testosterone undecanoate androgen replacement therapy clinical trials. ---
26  2015 The efficacy of combination treatment with injectable testosterone undecanoate and daily tadalafil for erectile dysfunction with testosterone deficiency syndrome. AMS, GAQ, IIEF, PDE5-Is
27  2015 [Effect and safety of testosterone undecanoate in the treatment of late-onset hypogonadism: a meta-analysis]. LOH
28  2014 Effect of testosterone undecanoate hormone on sperm and its level in the hemolymph of male mud spiny lobster, Panulirus polyphagus. ELISA
29  2014 Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. IPSS, LUTS, PSA, PVR
30  2014 Er-Xian Decoction, a traditional Chinese herbal formula, intervening early in hypothalamic-pituitary axis of male rats with delayed puberty. EXD, FSH, GnRH, HPT, LH, SD, TCM
31  2014 Injectable testosterone undecanoate for the treatment of hypogonadism. HG, RCTs
32  2014 Is testosterone replacement therapy in males with hypogonadism cost-effective? An analysis in Sweden. ICER, LOH, QALYs, TRT
33  2014 Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. BMI, ED, HDL, LDL, LOH, MetS
34  2014 Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. ---
35  2014 The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). FT, PSA, TDS, TT
36  2013 Effect of testosterone undecanoate on hematological profiles, blood lipid and viscosity and plasma testosterone level in castrated rabbits. FBN, Hb, Hct, HDL-C, LDL-C, TC, TG
37  2013 Effects of low-dose testosterone undecanoate treatment on bone mineral density and bone turnover markers in elderly male osteoporosis with low serum testosterone. BMD
38  2013 Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. BFM, BMD, DEXA, LBM, TD
39  2013 Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. PSA, TD, TT
40  2013 Experimental endocrine manipulation by contraceptive regimen in the male marmoset (Callithrix jacchus). NETE
41  2013 Induction of rat germ cell apoptosis by testosterone undecanoate and depot medroxyprogesterone acetate and correlation of apoptotic cells with sperm concentration. DMPA
42  2013 IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. ADRs, PSA
43  2013 Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. AMS, ED, EF, IIEF
44  2013 UGT2B17 Genotype and the Pharmacokinetic Serum Profile of Testosterone during Substitution Therapy with Testosterone Undecanoate. A Retrospective Experience from 207 Men with Hypogonadism. LH, TG
45  2012 Androgen replacement therapy improves psychological distress and health-related quality of life in late onset hypogonadism patients in Chinese population. AMS, HADS, PSS
46  2012 Complete sperm suppression induced by dienogest plus testosterone undecanoate is associated with down-regulation in the expression of upstream steroidogenic enzyme genes in rat testis. BW, DNG, StAR
47  2012 Integrity of the blood-testis barrier in healthy men after suppression of spermatogenesis with testosterone and levonorgestrel. LNG
48  2012 Steroid hormones for contraception in men. MENT, RCTs, TE
49  2012 Testosterone-induced prostate growth is blocked by co- and preadministration of norethisterone enanthate in castrated cynomolgus monkeys. NET, NETE
50  2011 A placebo-controlled, randomized clinical trial using testosterone undecanoate with injectable norethisterone enanthate: effect on anthropometric, metabolic and biochemical parameters. BMI, NETE
51  2011 Androgen substitution with testosterone undecanoate in survivors of bilateral testicular cancer requires individually-adjusted injection intervals. cFT, GCTC, TT
52  2011 Production and characterization of testosterone undecanoate-loaded NLC for oral bioavailability enhancement. ---
53  2011 Steady-state pharmacokinetics of oral testosterone undecanoate with concomitant inhibition of 5alpha-reductase by finasteride. DHT
54  2011 The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism. AR, BT, CAG, FT, HH, SHBG
55  2010 A safety study of administration of parenteral testosterone undecanoate to elderly men over minimally 24 months. ---
56  2010 Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. AMS, CI, IIEF-5, MetS, SD
57  2010 Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. BMI, CIMT, HOMA-IR, hs-CRP, IDF, MS, NCEP ATP III, PLB
58  2010 Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. HOMA, mo, MS
59  2010 Factors influencing time course of pain after depot oil intramuscular injection of testosterone undecanoate. ANOVA, IM
60  2010 Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial. DHT, IM
61  2010 Testosterone undecanoate in the treatment of male hypogonadism. ---
62  2010 Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints. AMS, BMI, HDL, LDL, LOH, PSA
63  2009 Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men. TE
64  2009 Levonorgestrel enhances spermatogenesis suppression by testosterone with greater alteration in testicular gene expression in men. LNG
65  2009 Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. ---
66  2009 Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. AMS, LOH
67  2009 Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. FtM
68  2009 Trials for development of once-a-month injectable, hormonal male contraceptive using dienogest plus testosterone undecanoate: dose standardization, efficacy and reversibility studies in rats. BW, DNG
69  2008 Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism. TE
70  2008 Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease. ---
71  2008 Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome. ---
72  2008 Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals. DHT, FtM
73  2008 Male hormonal contraception: a double-blind, placebo-controlled study. ENG
74  2008 Predictors for partial suppression of spermatogenesis of hormonal male contraception. AR, FSH, FSHR, LH, PCR
75  2008 Proteomic analysis of testis biopsies in men treated with injectable testosterone undecanoate alone or in combination with oral levonorgestrel as potential male contraceptive. hnRNP K, LNG, P4HB
76  2007 A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate. ---
77  2007 An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. ---
78  2007 Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. AR
79  2007 Long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. ---
80  2007 Recent trends in the treatment of testosterone deficiency syndrome. TDS
81  2007 Steroid hormones for contraception in men. MENT, TE
82  2007 The effect of food composition on serum testosterone levels after oral administration of Andriol Testocaps. DHT, GC-MS
83  2007 transient scrotal hyperthermia and levonorgestrel enhance testosterone-induced spermatogenesis suppression in men through increased germ cell apoptosis. LNG
84  2006 Double blind randomized placebo-controlled trial on the effects of testosterone supplementation in elderly men with moderate to low testosterone levels: design and baseline characteristics [ISRCTN23688581]. ---
85  2006 Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men. AUC, NETE
86  2006 Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido). ---
87  2006 Use of isotope ratio mass spectrometry to detect doping with oral testosterone undecanoate: inter-individual variability of 13C/12C ratio. IRMS
88  2006 [Effect of intra-testicular testosterone withdrawal on the expression of alpha-catenin in the adult rat testis]. ---
89  2005 Effect of oral testosterone undecanoate on visuospatial cognition, mood and quality of life in elderly men with low-normal gonadal status. cBT, FTI, GDS, MMSE, QOL, VSP
90  2005 Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis, and prostate. NETE
91  2005 Pharmacokinetics and pharmacodynamics of injectable testosterone undecanoate in castrated cynomolgus monkeys (Macaca fascicularis) are independent of different oil vehicles. ---
92  2004 Hormonal contraception in Chinese men: variations in suppression of spermatogenesis with injectable testosterone undecanoate and levonorgestrel implants. LNG
93  2004 Male hormonal contraception: effects of injections of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in chinese men. DMPA
94  2004 Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in chinese men. IM, LNG
95  2004 Quantitative (stereological) study of incomplete spermatogenic suppression induced by testosterone undecanoate injection in rats. ---
96  2004 Randomized, crossover comparison study of the short-term effect of oral testosterone undecanoate and intramuscular testosterone depot on linear growth and serum bone alkaline phosphatase. bALP, LLL, LLLV
97  2004 Serum lipids in oophorectomized women during estrogen and testosterone replacement therapy. HDL, LDL, SHBG
98  2004 [Effect of injection of testosterone undecanoate and depot medroxyprogesterone acetate on the suppression of spermatogenesis]. DMPA
99  2003 A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. ---
100  2003 Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. ---